UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (589549) 589549
Newsletter (54234) 54234
Newspaper Article (17517) 17517
Magazine Article (2875) 2875
Conference Proceeding (1269) 1269
Book / eBook (877) 877
Dissertation (601) 601
Web Resource (382) 382
Transcript (299) 299
Book Chapter (176) 176
Reference (166) 166
Publication (131) 131
Streaming Video (112) 112
Government Document (104) 104
Journal / eJournal (38) 38
Book Review (26) 26
Report (7) 7
Paper (4) 4
Trade Publication Article (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (466645) 466645
science & technology (366303) 366303
life sciences & biomedicine (350330) 350330
antineoplastic agents (259062) 259062
female (223959) 223959
oncology (190134) 190134
male (183977) 183977
biological and medical sciences (182489) 182489
medical sciences (177535) 177535
cancer (150133) 150133
middle aged (140892) 140892
animals (139271) 139271
antimitotic agents (133495) 133495
pharmacology. drug treatments (131886) 131886
aged (116350) 116350
adult (113733) 113733
antineoplastic agents - therapeutic use (108263) 108263
chemotherapy (107174) 107174
antineoplastic combined chemotherapy protocols - therapeutic use (106454) 106454
antineoplastic agents - pharmacology (100916) 100916
care and treatment (88331) 88331
research (78869) 78869
mice (75822) 75822
tumors (73361) 73361
cell line, tumor (73299) 73299
treatment outcome (67805) 67805
pharmacology & pharmacy (63950) 63950
prognosis (43040) 43040
antineoplastic agents - administration & dosage (42981) 42981
combined modality therapy (42639) 42639
neoplasms - drug therapy (41829) 41829
antineoplastic agents - adverse effects (40551) 40551
health aspects (40294) 40294
analysis (40193) 40193
apoptosis (38806) 38806
oncology, experimental (37591) 37591
apoptosis - drug effects (37184) 37184
aged, 80 and over (36398) 36398
hematology (36367) 36367
breast neoplasms - drug therapy (35996) 35996
dose-response relationship, drug (34707) 34707
drug therapy (34675) 34675
antineoplastic agents - chemistry (33811) 33811
breast cancer (32914) 32914
general aspects (32213) 32213
neoplasm staging (31322) 31322
antineoplastic combined chemotherapy protocols - adverse effects (31011) 31011
cell proliferation - drug effects (31007) 31007
abridged index medicus (30376) 30376
adolescent (30317) 30317
biochemistry & molecular biology (29606) 29606
retrospective studies (29273) 29273
tumor cells, cultured (29192) 29192
chemistry (28199) 28199
lung neoplasms - drug therapy (27577) 27577
time factors (26657) 26657
cell survival - drug effects (25871) 25871
medicine & public health (25794) 25794
physical sciences (25697) 25697
survival rate (25158) 25158
disease-free survival (24454) 24454
metastasis (23442) 23442
child (23198) 23198
follow-up studies (22957) 22957
cisplatin - administration & dosage (22920) 22920
rats (22079) 22079
survival analysis (22063) 22063
antineoplastic combined chemotherapy protocols - administration & dosage (21931) 21931
drug screening assays, antitumor (21210) 21210
drug administration schedule (21053) 21053
breast neoplasms - pathology (20882) 20882
immunotherapy (20295) 20295
drugs (19907) 19907
doxorubicin - administration & dosage (19522) 19522
chemotherapy, adjuvant (19502) 19502
surgery (19016) 19016
mice, nude (19013) 19013
antineoplastic agents, phytogenic - pharmacology (18873) 18873
drug resistance, neoplasm (18857) 18857
structure-activity relationship (18703) 18703
chemistry, medicinal (18626) 18626
fluorouracil - administration & dosage (18573) 18573
antineoplastic agents - chemical synthesis (17962) 17962
clinical trials as topic (17876) 17876
risk factors (17720) 17720
cell biology (17532) 17532
clinical trials (16644) 16644
cancer therapies (16596) 16596
molecular structure (16554) 16554
hematology, oncology and palliative medicine (16541) 16541
neoplasm metastasis (16150) 16150
genetic aspects (15789) 15789
medical research (15724) 15724
cyclophosphamide - administration & dosage (15710) 15710
universities and colleges (15429) 15429
xenograft model antitumor assays (15202) 15202
drug resistance (15173) 15173
remission induction (15120) 15120
pharmaceutical industry (14987) 14987
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (456) 456
Online Resources - Online (375) 375
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (56) 56
Collection Dvlpm't (Acquisitions) - Vendor file (46) 46
Collection Dvlpm't (Acquisitions) - Closed Orders (36) 36
UofT at Mississauga - Stacks (16) 16
Gerstein Science - Periodical Stacks (14) 14
Scarborough Hospital - Online (6) 6
Chemistry (A D Allen) - Stacks (5) 5
Scarborough Hospital - Birchmount (5) 5
Lakeridge Health Sciences - Online (4) 4
Gerstein Science - Bindery (3) 3
Robarts - Stacks (3) 3
St. Michael's Hospital - Stacks (3) 3
Sunnybrook Health Sciences Centre - Sunnybrook Reference (3) 3
UTL at Downsview - May be requested (3) 3
Credit Valley Hospital - Stacks (2) 2
East Asian (Cheng Yu Tung) - Reference (2) 2
Gerstein Science - Circulation Desk (2) 2
Gerstein Science - Reference (2) 2
Scarborough Hospital - General (2) 2
Sunnybrook Health Sciences Centre - Online (2) 2
Baycrest Hospital - Wellness Library (1) 1
Credit Valley Hospital - Special Collections (1) 1
Dentistry (Harry R Abbott) - Course Reserves (1) 1
Dentistry (Harry R Abbott) - Stacks (1) 1
Earth Sciences (Noranda) - Stacks (1) 1
Engineering & Comp. Sci. - Stacks (1) 1
Gerstein Science - Theses (1) 1
Humber River Regional Hospital - Online (1) 1
Lakeridge Health Sciences - Oshawa (1) 1
Markham Stouffville Hospital - Stacks (1) 1
New College (Ivey) - Stacks (1) 1
Providence Healthcare - Reference (1) 1
Providence Healthcare - Stacks (1) 1
Scarborough Hospital - Hospital Department (1) 1
Scarborough Hospital - Sunnybrook Stacks (1) 1
St. Michael's College (John M. Kelly) - 2nd Floor (1) 1
St. Michael's Hospital - Online (1) 1
St. Michael's Hospital - Pharmacy (1) 1
Stacks (1) 1
Sunnybrook Health Sciences Centre - Missing (1) 1
Sunnybrook Health Sciences Centre - Oshawa (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Patient Education (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Periodicals (1) 1
Thomas Fisher Rare Book - Rare Book (1) 1
University College (Laidlaw) - Stacks (1) 1
UofT Schools - Stacks (1) 1
UofT at Scarborough - Stacks (1) 1
West Park Healthcare Centre - Stacks (1) 1
Women's College Hospital - Online (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (631866) 631866
Japanese (20129) 20129
French (7954) 7954
Chinese (7656) 7656
Russian (5384) 5384
German (5056) 5056
Italian (2634) 2634
Spanish (1575) 1575
Polish (1559) 1559
Portuguese (878) 878
Hungarian (725) 725
Czech (666) 666
Danish (390) 390
Dutch (336) 336
Norwegian (267) 267
Swedish (242) 242
Ukrainian (179) 179
Korean (163) 163
Hebrew (162) 162
Finnish (139) 139
Croatian (130) 130
Bulgarian (124) 124
Serbian (121) 121
Slovak (84) 84
Romanian (79) 79
Turkish (30) 30
Lithuanian (28) 28
Bosnian (13) 13
Greek (7) 7
Afrikaans (3) 3
Slovenian (3) 3
Icelandic (2) 2
Amharic (1) 1
Arabic (1) 1
Breton (1) 1
Catalan (1) 1
Kurdish (1) 1
Latin (1) 1
Manx (1) 1
Nauru (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Anti-cancer drug design, ISSN 0266-9536, 1985
Journal
Cancer chemotherapy and pharmacology, ISSN 0344-5704, 1978
Journal
Cancer chemotherapy and pharmacology, ISSN 0344-5704, 8/2011, Volume 68, Issue 2, pp. 445 - 455
Fisetin | Lewis lung carcinoma | Angiogenesis | Antitumour activity | Cyclophosphamide | Medicine & Public Health | Cancer Research | Oncology | Cytotoxicity | EA·hy 926 endothelial cells | Pharmacology/Toxicology | Flavonoid | EA•hy 926 endothelial cells | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Science & Technology | Tumors of the respiratory system and mediastinum | Biological and medical sciences | Medical sciences | Antineoplastic agents | Pharmacology. Drug treatments | Pneumology | NIH 3T3 Cells | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Tubulin Modulators - pharmacology | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents, Alkylating - pharmacology | Flavonoids - adverse effects | Antineoplastic Agents, Alkylating - administration & dosage | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Flavonoids - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Angiogenesis Inhibitors - administration & dosage | Antineoplastic Agents, Phytogenic - administration & dosage | Angiogenesis Inhibitors - therapeutic use | Flavonoids - administration & dosage | Tubulin Modulators - administration & dosage | Female | Flavonoids - pharmacology | Antineoplastic Agents, Phytogenic - therapeutic use | Angiogenesis Inhibitors - adverse effects | Antineoplastic Agents, Phytogenic - adverse effects | Cell Line | Cell Survival - drug effects | Tubulin Modulators - adverse effects | Mice, Inbred C57BL | Angiogenesis Inhibitors - pharmacology | Tubulin Modulators - therapeutic use | Carcinoma, Lewis Lung - drug therapy | Antineoplastic Agents, Alkylating - therapeutic use | Cell Movement - drug effects | Animals | Tumor Burden - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Endothelial Cells - cytology | Neovascularization, Pathologic - drug therapy | Cyclophosphamide - pharmacology | Carcinoma, Lewis Lung - pathology | Cell Proliferation - drug effects | Mice | Antineoplastic Agents, Alkylating - adverse effects | Antineoplastic Agents, Phytogenic - pharmacology | Cell Cycle - drug effects | Endothelial Cells - drug effects | Antimitotic agents | Flavonoids | Flavones | Lung cancer | Bioflavonoids | Accountants | Drug therapy, Combination | Universities and colleges | Endothelium | Tumors | Index Medicus | cytology | Antineoplastic Agents, Phytogenic | pathology | Cell Proliferation | Endothelial Cells | Tubulin Modulators | Neovascularization, Pathologic | fisetin | administration & dosage | pharmacology | flavonoid | Carcinoma, Lewis Lung | Antineoplastic Agents, Alkylating | cytotoxicity | drug therapy | Cell Survival | angiogenesis | Antineoplastic Combined Chemotherapy Protocols | drug effects | Tumor Burden | Angiogenesis Inhibitors | EA.hy 926 | Cell Cycle | antitumour activity | adverse effects | therapeutic use | Cell Movement
Journal Article
Anti-cancer drugs, ISSN 0959-4973, 1990
Journal
Molecular cancer therapeutics, ISSN 1535-7163, 2001
Journal
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 11/2009, Volume 27, Issue 33, pp. 5538 - 5546
Life Sciences & Biomedicine | Oncology | Science & Technology | Triazoles - administration & dosage | Triazoles - adverse effects | Postmenopause - drug effects | Receptors, Estrogen - metabolism | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carcinoma - mortality | Receptors, Progesterone - genetics | Breast Neoplasms - metabolism | Receptors, Progesterone - metabolism | Dose-Response Relationship, Drug | Nitriles - administration & dosage | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Invasiveness - pathology | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Carcinoma - pathology | Carcinoma - secondary | Carcinoma - drug therapy | Receptors, Estrogen - genetics | Double-Blind Method | Drug Administration Schedule | Risk Assessment | Biomarkers, Tumor - analysis | Antineoplastic Agents, Hormonal - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Maximum Tolerated Dose | Breast Neoplasms - pathology | Quinazolines - adverse effects | Survival Analysis | Breast Neoplasms - mortality | Aged | Biomarkers, Tumor - genetics | Carcinoma - metabolism | Neoplasm Staging | Nitriles - adverse effects | Index Medicus | Carcinoma | Quinazolines | Breast Neoplasms | Life Sciences | Immunology | Triazoles | Postmenopause | Nitriles | Antineoplastic Agents, Hormonal | Tumor Markers, Biological | Receptors, Estrogen | Neoplasm Invasiveness | Antineoplastic Combined Chemotherapy Protocols | Receptor, erbB-2 | Receptors, Progesterone | Kaplan-Meiers Estimate
Journal Article
The New England journal of medicine, ISSN 0028-4793, 11/2019, Volume 381, Issue 21, pp. 2020 - 2031
Journal Article
2007, ISBN 9780195187762, ix, 355
Book
European journal of medicinal chemistry, ISSN 0223-5234, 10/2014, Volume 85, pp. 418 - 437
Inhibitor | Cross-coupling reaction | DNPH1 | Nucleoside analogues | Crystal structure | Cancer | Purine Nucleotides - pharmacology | Antineoplastic Agents - chemical synthesis | Humans | Proto-Oncogene Proteins - chemistry | Structure-Activity Relationship | Enzyme Inhibitors - chemical synthesis | Molecular Targeted Therapy | Purine Nucleotides - chemistry | N-Glycosyl Hydrolases - chemistry | Purine Nucleotides - metabolism | Antineoplastic Agents - metabolism | Enzyme Inhibitors - chemistry | Drug Design | Antineoplastic Agents - pharmacology | Proto-Oncogene Proteins - metabolism | Proto-Oncogene Proteins - antagonists & inhibitors | Chemistry Techniques, Synthetic | Enzyme Inhibitors - metabolism | N-Glycosyl Hydrolases - antagonists & inhibitors | Enzyme Inhibitors - pharmacology | Rats | Nuclear Proteins - metabolism | Purine Nucleotides - chemical synthesis | Antineoplastic Agents - chemistry | Nuclear Proteins - chemistry | N-Glycosyl Hydrolases - metabolism | Animals | Nuclear Proteins - antagonists & inhibitors | Cell Line, Tumor | Protein Conformation | Molecular Docking Simulation | Drug Screening Assays, Antitumor | Enzymes | Colon cancer | Leukemia | Crystals | Hydrolases | Nucleotides | Structure | Index Medicus | Nuclear Proteins/chemistry | Purine Nucleotides/metabolism | Proto-Oncogene Proteins/antagonists & inhibitors | Enzyme Inhibitors/metabolism | Enzyme Inhibitors/pharmacology | Life Sciences | Antineoplastic Agents/pharmacology | N-Glycosyl Hydrolases/antagonists & inhibitors | Nuclear Proteins/antagonists & inhibitors | N-Glycosyl Hydrolases/metabolism | Nuclear Proteins/metabolism | Purine Nucleotides/chemistry | Enzyme Inhibitors/chemistry | Purine Nucleotides/chemical synthesis | Enzyme Inhibitors/chemical synthesis | Antineoplastic Agents/metabolism | N-Glycosyl Hydrolases/chemistry | Proto-Oncogene Proteins/chemistry | Biochemistry, Molecular Biology | Proto-Oncogene Proteins/metabolism | Purine Nucleotides/pharmacology | Antineoplastic Agents/chemistry | Antineoplastic Agents/chemical synthesis
Journal Article
Annals of oncology, ISSN 0923-7534, 12/2012, Volume 23, Issue 12, pp. 3069 - 3074
Journal Article
Science (American Association for the Advancement of Science), ISSN 0036-8075, 5/2010, Volume 328, Issue 5981, pp. 1031 - 1035
Molecules | Intravenous injections | Medical treatment | REPORTS | Antineoplastics | Antibodies | Liposomes | Dosage | Prostate cancer | Tumors | Cancer | Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Biological and medical sciences | Chemotherapy | Medical sciences | Antineoplastic agents | Pharmacology. Drug treatments | Neoplasms - metabolism | Doxorubicin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Neuropilin-1 - metabolism | Albumin-Bound Paclitaxel | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Capillary Permeability - drug effects | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Paclitaxel - pharmacokinetics | Antineoplastic Agents - administration & dosage | Albumins - therapeutic use | Antibodies, Monoclonal, Humanized | Antineoplastic Agents - pharmacokinetics | Paclitaxel - administration & dosage | Doxorubicin - administration & dosage | Oligopeptides - pharmacokinetics | Antibodies, Monoclonal - pharmacokinetics | Albumins - administration & dosage | Neoplasms - blood supply | Oligopeptides - metabolism | Permeability | Paclitaxel - therapeutic use | Doxorubicin - pharmacokinetics | Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Albumins - pharmacokinetics | Animals | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mice | Oligopeptides - administration & dosage | Oligopeptides - pharmacology | Trastuzumab | Antimitotic agents | Peptides | Research | Drug therapy | Health aspects | Index Medicus | Drugs | Nanoparticles | Side effects | Doxorubicin | Constraining
Journal Article